Moderna, Inc. and Immatics N.V. announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.43 USD | -1.19% | -4.02% | +18.04% |
05-15 | Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating | MT |
05-14 | Immatics' Q1 Loss Narrows. Revenue Rises | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
134.4 USD | +0.85% | -7.46% | 51.51B | ||
12.43 USD | -1.19% | -4.02% | 1.28B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.04% | 1.28B | |
+15.85% | 122B | |
+18.91% | 113B | |
+4.43% | 22.84B | |
-18.63% | 20.72B | |
-13.76% | 16.39B | |
-16.61% | 16.51B | |
-43.53% | 15.83B | |
+1.75% | 13.49B | |
+28.07% | 11.67B |
- Stock Market
- Equities
- IMTX Stock
- News Immatics N.V.
- Moderna, Inc. and Immatics N.V. Announces Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics